BiotechTube
Home/NeuClone/David W. Anstice
DW

David W. Anstice

Non‑Executive Director

NeuClone

Therapeutic Areas

OncologyImmunologyBone HealthInfectious Diseases

NeuClone Pipeline

DrugIndicationPhase
Herceptin (Trastuzumab) BiosimilarHER2‑positive Breast CancerPhase 1
Stelara (Ustekinumab) BiosimilarPsoriasis / Crohn's DiseasePhase 1
Perjeta (Pertuzumab) BiosimilarHER2‑positive Breast CancerProcess Scale‑up
Opdivo (Nivolumab) BiosimilarVarious Cancers (PD‑1 inhibitor)Process Scale‑up
Keytruda (Pembrolizumab) BiosimilarVarious Cancers (PD‑1 inhibitor)Process Scale‑up
Prolia/XGEVA (Denosumab) BiosimilarBone Metastases / OsteoporosisProcess Scale‑up
Humira (Adalimumab) BiosimilarAutoimmune DiseasesEarly Preclinical
Synagis (Palivizumab) BiosimilarRSV ProphylaxisEarly Preclinical

Leadership Team at NeuClone

DN
Dr. Noelle Sunstrom
CEO, Founder, Director
DR
Dr. Russell J. Howard
Executive Chairman
JM
John Macphillamy
Chief Financial Officer, General Counsel, Executive Director
DP
Dr. Parisa Asvadi
Chief Development Officer
View full NeuClone profile